Phase 2 Study of Gemzar, Taxol & Avastin Combination as 1st Line Treatment for Metastatic Breast Cancer
Trial ID or NCT#
Status
Purpose
Single-institution phase 2 trial investigating the efficacy of capecitabine, oxaliplatin and bevacizumab for patients with metastatic neuroendocrine tumors.
Official Title
Phase II Open Label Study of Gemcitabine, Paclitaxel and Bevacizumab Combination as First Line Treatment for Metastatic Breast Cancer
Eligibility Criteria
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Mary Chen
6507238686
View on ClinicalTrials.gov